SHIFT Newsroom · UK
GLP-1 medicines and anaesthesia: what the new UK study means
New UK findings underline why your surgical team needs to know about your weight-management medicine, including private prescriptions.
The Association of Anaesthetists reported new observational findings on 16 September 2026, covering 47,039 adults at 119 UK sites.
Regurgitation (stomach contents coming back up) and/or aspiration (contents entering the lungs) occurred in 19 of 1,348 GLP-1 users (1.41%), compared with 57 of 45,691 non-users (0.12%). The 19 events comprised 17 regurgitations and two aspirations. The widely reported eleven-fold comparison concerns the combined outcome, not aspiration alone.
This association does not establish that the medicines caused the difference. Obesity, diabetes and possible under-reporting could affect the comparison. These figures cannot predict an individual's risk. This briefing uses the association's announcement; we have not independently reviewed the full journal paper.
SHIFT’s take
For members, the useful next step is preparation. If you have a procedure involving general anaesthesia or deep sedation coming up, tell the pre-assessment team early about your medicine, including one obtained privately or online. The hospital may not have that prescription in your records.
Have the medicine name, dose and date of your last dose ready. Ask the team what instructions apply to your medicine and fasting, and who to contact if those instructions are unclear. If they advise a pause, ask how and when to restart.
SHIFT's interpretation: this is a reminder that support needs to cover real-life situations beyond the prescription. Clear information can help you ask the right questions, wherever your medicine comes from. Decisions about your treatment belong with your prescriber and anaesthetic team.
Known facts
- The MHRA advises patients to tell their healthcare team and anaesthetist about GLP-1 treatment before a procedure.